Announcements - OBI Pharma 台灣浩鼎

2024.May.10

Announcement of the Consolidated Financial Statements for the first quarter of 2024 were approved by the Board of Directors.

2024.May.10

Correct consolidated financial reports from 2023Q1 to Q4, independent 2024Q4 financial report, and iXBRL, which have no impact on income and losses and net assets.

2024.May.02

Announcement on behalf of OBIGEN that TFDA clears OBI-858’s IND application for Phase II human clinical trial

2024.Apr.25

Announcement of the Company’s board meeting date to approve 2024Q1 consolidated financial report

2024.Apr.12

Announcement on behalf of Amaran of not Distributing Dividends of 2023

2024.Apr.12

Announcement on behalf of Amaran that the BOD resolved to convene the 2024 Annual General Shareholders' Meeting

2024.Mar.20

Announcement on behalf of OBIGEN of not Distributing Dividends of 2023

2024.Mar.20

Announcement on behalf of OBIGEN that the BOD resolved to issue 2024 employee stock options and the subscription rules.

2024.Mar.20

Announcement on behalf of OBIGEN that the BOD resolved to convene the 2024 Annual General Shareholders' Meeting

2024.Mar.11

Announcement of BOD’s resolution to lift the non-competition restrictions for managerial officers

News

Latest News

Events

Latest events